Lupin is currently trading at Rs. 2266.55, up by 15.45 points or 0.69% from its previous closing of Rs. 2251.10 on the BSE.

The scrip opened at Rs. 2254.65 and has touched a high and low of Rs. 2270.40 and Rs. 2254.65 respectively. So far 9084 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2,270.40 on 25-Feb-2026 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 2270.40 and Rs. 2204.85 respectively. The current market cap of the company is Rs. 103312.33 crore.

The promoters holding in the company stood at 46.89%, while Institutions and Non-Institutions held 47.07% and 6.03% respectively.

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution 10 mg/mL. Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB, Inc. and is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. Following the approval, the company initiated the launch of Brivaracetam Oral Solution in the United States.

Brivaracetam Oral Solution (RLD Briviact) had an estimated annual sale of $135 million in the U.S. (IQVIA MAT December 2025). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.